Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis
Abstract Purpose Osteoporosis poses a challenge to public health, causing fragility fractures, especially in postmenopausal women. Abaloparatide (ABL) is an effective anabolic agent to improve bone formation and resorption among postmenopausal women with osteoporosis. Our meta-analysis aims to asses...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | Journal of Orthopaedic Surgery and Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13018-023-03595-x |
| _version_ | 1797864061554130944 |
|---|---|
| author | Pan Hong Ruikang Liu Saroj Rai JiaJia Liu YeMing Zhou Yu Zheng Jin Li |
| author_facet | Pan Hong Ruikang Liu Saroj Rai JiaJia Liu YeMing Zhou Yu Zheng Jin Li |
| author_sort | Pan Hong |
| collection | DOAJ |
| description | Abstract Purpose Osteoporosis poses a challenge to public health, causing fragility fractures, especially in postmenopausal women. Abaloparatide (ABL) is an effective anabolic agent to improve bone formation and resorption among postmenopausal women with osteoporosis. Our meta-analysis aims to assess the effectiveness and safety of ABL versus teriparatide (TPTD) in improving bone mineral density (BMD). Methods We searched Medline, Embase, Web of Science, Cochrane databases and Clinicaltrial.gov until September 2, 2022. We included data from randomized controlled trials (RCTs) and post hoc analyses of RCTs. Outcomes included BMD change from baseline and risks of adverse events. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) tool was used to evaluate the quality of outcomes. Results Four studies including 16 subgroups were included in this study. In particular, RCTs with head-to-head comparisons of ABL and TPTD were used in the meta-analysis, and all were from manufacturer-sponsored trials. All parameters in 24 weeks except lumbar spine (versus TPTD) showed significant advantages in the ABL group. Only the results of two subgroups in ABL versus TPTD demonstrated High GRADE quality (femoral neck: weighted mean difference (WMD) = 1.58 [0.52, 2.63]; Total hip: WMD = 1.46 [0.59, 2.32]). However, our fracture data were insufficient. Besides, we found no evident difference in serious adverse events or deaths in either group and the incidence of hypercalcemia in the ABL group lessened by 51% compared with the TPTD group. Nevertheless, compared with placebo, ABL demonstrated higher risks of nausea and palpitations. Conclusion ABL demonstrated a beneficial effect on BMD compared to both placebo and TPTD for postmenopausal women with osteoporosis. ABL also had insignificantly lowered adverse event risk than TPTD. ABL is an alternative for patients with postmenopausal osteoporosis. |
| first_indexed | 2024-04-09T22:45:30Z |
| format | Article |
| id | doaj.art-08c82339db194add85b712c7ae0a1823 |
| institution | Directory Open Access Journal |
| issn | 1749-799X |
| language | English |
| last_indexed | 2024-04-09T22:45:30Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Orthopaedic Surgery and Research |
| spelling | doaj.art-08c82339db194add85b712c7ae0a18232023-03-22T11:51:39ZengBMCJournal of Orthopaedic Surgery and Research1749-799X2023-02-0118111210.1186/s13018-023-03595-xIs abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysisPan Hong0Ruikang Liu1Saroj Rai2JiaJia Liu3YeMing Zhou4Yu Zheng5Jin Li6Department of Orthopaedic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Orthopaedics and Trauma Surgery, Dubai Investment Park Br, Karama Medical CenterFirst Clinical School, Tongji Medical College, Huazhong University of Science and TechnologyBasic Medical School, Tongji Medical College, Huazhong University of Science and TechnologyBasic Medical School, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Orthopaedic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Purpose Osteoporosis poses a challenge to public health, causing fragility fractures, especially in postmenopausal women. Abaloparatide (ABL) is an effective anabolic agent to improve bone formation and resorption among postmenopausal women with osteoporosis. Our meta-analysis aims to assess the effectiveness and safety of ABL versus teriparatide (TPTD) in improving bone mineral density (BMD). Methods We searched Medline, Embase, Web of Science, Cochrane databases and Clinicaltrial.gov until September 2, 2022. We included data from randomized controlled trials (RCTs) and post hoc analyses of RCTs. Outcomes included BMD change from baseline and risks of adverse events. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) tool was used to evaluate the quality of outcomes. Results Four studies including 16 subgroups were included in this study. In particular, RCTs with head-to-head comparisons of ABL and TPTD were used in the meta-analysis, and all were from manufacturer-sponsored trials. All parameters in 24 weeks except lumbar spine (versus TPTD) showed significant advantages in the ABL group. Only the results of two subgroups in ABL versus TPTD demonstrated High GRADE quality (femoral neck: weighted mean difference (WMD) = 1.58 [0.52, 2.63]; Total hip: WMD = 1.46 [0.59, 2.32]). However, our fracture data were insufficient. Besides, we found no evident difference in serious adverse events or deaths in either group and the incidence of hypercalcemia in the ABL group lessened by 51% compared with the TPTD group. Nevertheless, compared with placebo, ABL demonstrated higher risks of nausea and palpitations. Conclusion ABL demonstrated a beneficial effect on BMD compared to both placebo and TPTD for postmenopausal women with osteoporosis. ABL also had insignificantly lowered adverse event risk than TPTD. ABL is an alternative for patients with postmenopausal osteoporosis.https://doi.org/10.1186/s13018-023-03595-xAbaloparatideTeriparatideOsteoporosisPostmenopausal womenMeta-analysis |
| spellingShingle | Pan Hong Ruikang Liu Saroj Rai JiaJia Liu YeMing Zhou Yu Zheng Jin Li Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis Journal of Orthopaedic Surgery and Research Abaloparatide Teriparatide Osteoporosis Postmenopausal women Meta-analysis |
| title | Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis |
| title_full | Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis |
| title_fullStr | Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis |
| title_full_unstemmed | Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis |
| title_short | Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis |
| title_sort | is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis an updated meta analysis |
| topic | Abaloparatide Teriparatide Osteoporosis Postmenopausal women Meta-analysis |
| url | https://doi.org/10.1186/s13018-023-03595-x |
| work_keys_str_mv | AT panhong isabaloparatidemoreefficaciousonincreasingbonemineraldensitythanteriparatideforwomenwithpostmenopausalosteoporosisanupdatedmetaanalysis AT ruikangliu isabaloparatidemoreefficaciousonincreasingbonemineraldensitythanteriparatideforwomenwithpostmenopausalosteoporosisanupdatedmetaanalysis AT sarojrai isabaloparatidemoreefficaciousonincreasingbonemineraldensitythanteriparatideforwomenwithpostmenopausalosteoporosisanupdatedmetaanalysis AT jiajialiu isabaloparatidemoreefficaciousonincreasingbonemineraldensitythanteriparatideforwomenwithpostmenopausalosteoporosisanupdatedmetaanalysis AT yemingzhou isabaloparatidemoreefficaciousonincreasingbonemineraldensitythanteriparatideforwomenwithpostmenopausalosteoporosisanupdatedmetaanalysis AT yuzheng isabaloparatidemoreefficaciousonincreasingbonemineraldensitythanteriparatideforwomenwithpostmenopausalosteoporosisanupdatedmetaanalysis AT jinli isabaloparatidemoreefficaciousonincreasingbonemineraldensitythanteriparatideforwomenwithpostmenopausalosteoporosisanupdatedmetaanalysis |